CA180P52 DASATINIB/EXEMESTANE
Clinical Trial Program
Randomized double-blind phase II trial of exemestane (Aromasin®) plus dasatinib versus exemestane plus placebo in advanced ER+ breast cancer after disease progression on a non-steroidal aromatase inhibitor
Phase II
Status
Finished
Tumour subtype:
HR+
Scenario
Locally Advanced or Metastatic
SPONSOR
COLLABORATORS
PRINCIPAL INVESTIGATORS
José Baselga, MD, PhD (Hospital Universitari Vall d'Hebron, Barcelona)
